Adjuvant therapy is medication that is given after surgery to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining tumours.
Part A of this phase 3 CheckMate-914 study showed that adjuvant therapy with a combination of nivolumab plus ipilimumab did not improve survival in patients with kidney cancer who had already had surgery and were at moderate or high risk of the cancer returning.
There were no new side effects reported with the combination treatment compared with previous studies in solid tumours.
Part B of the study is ongoing and is comparing nivolumab to placebo as an adjuvant treatment for moderate to high risk kidney cancer patients.